[
    [
        {
            "time": "",
            "original_text": "医药生物行业2021年下半年投资策略：短期有扰动 长期发展趋势向好",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资策略",
                    "短期扰动",
                    "长期趋势"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业2021年下半年投资策略：短期有扰动 长期发展趋势向好",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)股东YINXIANG WANG等减持期满 合计减持94.32万股 减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "股东",
                    "减持",
                    "94.32万股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)股东YINXIANG WANG等减持期满 合计减持94.32万股 减持股份",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)：2名股东已合计减持94.32万股 减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "股东",
                    "减持",
                    "94.32万股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：2名股东已合计减持94.32万股 减持股份",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：股东YINXIANG WANG、FENLAI TAN共减持公司股份约94万股 减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "股东",
                    "减持",
                    "94万股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业：股东YINXIANG WANG、FENLAI TAN共减持公司股份约94万股 减持股份",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：BPI-16350胶囊获得药品联用临床试验批准",
            "features": {
                "keywords": [
                    "贝达药业",
                    "BPI-16350胶囊",
                    "临床试验",
                    "批准"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：BPI-16350胶囊获得药品联用临床试验批准",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]